Drugs / Concizumab
Concizumab
also known as
NNC172-2021 · Alhemo · Anti-TFPI · Concizumab-mtci · MAB-2021 · NN-7415 · NNC 0172-0000-2021 · NNC0172-2021
Monoclonal antibody targets TFPI
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | ALHEMO | — | 2025-07-31 | fda.gov ↗ |
| Approved | EU (EMA) | Alhemo | — | 2024-12-13 | europa.eu ↗ |
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT02490787 | Sep 2015 → Oct 2016 | hemophilia A | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01631942 | Jun → Sep 2012 | congenital hematological disorder, hemophilia A | Novo Nordisk A/S | Terminated | No outcome recorded |
| Phase 1 | NCT01555749 | Mar → May 2012 | hemophilia A, hemophilia B | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01228669 | Oct 2010 → Sep 2012 | congenital hematological disorder, hemophilia A, hemophilia B | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03196297 | Aug 2017 → Jun 2018 | hemophilia A, vascular hemostatic disease | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT03196284 | Aug 2017 → Sep 2018 | hemophilia A, hemophilia B | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05135559 | Mar 2022 → Apr 2026 overdue | hemophilia | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04082429 | Nov 2019 → Jul 2022 overdue | hemophilia A, hemophilia B | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04083781 | Oct 2019 → Dec 2021 overdue | hemophilia A, hemophilia B | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04921956 | — | hemophilia | Novo Nordisk A/S | Available | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-03-16 | Novo Nordisk A/S | Novo Nordisk pauses the clinical trials investigating concizumab (anti-TFPI mAB) in haemophilia A and B with or without inhibitors novonordisk.com ↗ |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Concizumab | “Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial.” PMID 25641556 ↗ Apr 2015 |
| Known as | Alhemo | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297730 ↗ |
| Known as | Anti-TFPI | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297730 ↗ |
| Known as | Concizumab-mtci | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297730 ↗ |
| Known as | MAB-2021 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297730 ↗ |
| Known as | NN-7415 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297730 ↗ |
| Known as | NNC 0172-0000-2021 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297730 ↗ |
| Known as | NNC0172-2021 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297730 ↗ |
| Known as | NNC172-2021 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01555749 ↗ |
| Action | Inhibit | “anti-tissue factor pathway inhibitor” PMID 40166710 ↗ Feb 2025 |
| Modality | Monoclonal antibody | “A monoclonal antibody (concizumab) targeting tissue factor pathway inhibitor (TFPI)” PMID 25641556 ↗ Apr 2015 |
| Route | Subcutaneous | “administered subcutaneously” NCT01555749 ↗ |
| Target | TFPI | “A monoclonal antibody (concizumab) targeting tissue factor pathway inhibitor (TFPI)” PMID 25641556 ↗ Apr 2015 |